CardioComm Solutions, Inc.

CardioComm Solutions, Inc. develops advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets worldwide. The company's technology is used in a range of products for the recording, transmission, viewing, analyzing, reporting, and storage of ECGs for arrhythmia screening, diagnosis, and management of cardiac patients. Its proprietary device connectivity and ECG management technologies are used in medical, consumer, clinical research, and telemedicine solutions. The company's software products include Global ECG Management System (GEMS), a software solution for cardiac event monitoring; GlobalCardio 12 Lead, a web enabled ECG device that is EMR compatible; and GEMS Lite for Windows, an electronic ECG receiving system. It also offers software modules, such as GEMS WIN Air, a live wireless ECG monitoring solution; AutoAttendant, which allows healthcare providers to focus on providing patient care; GEMS HL7 Interface that allows patient and follow-up information to be sent in an HL7 message format to other EMR systems that are HL7 compliant; and GlobalCardio EMR integration that enables bidirectional movement of data, including patient information, reports, and links. In addition, the company provides hardware products comprising HeartCheck PEN and HeartCheck, which are handheld ECG monitors; and Sirona telephonic and wireless event recorders, as well as HeartCheck CardiBeat. Further, it offers ASP services, including C4 ECG management services; and HeartCheck SMART Monitoring. Additionally, the company provides other products comprising GlobalCardio 3 Lead; ECG Viewer SDK; QRS Diagnostic; and QRS 12 Lead Universal products. CardioComm Solutions, Inc. was incorporated in 1989 and is headquartered in Toronto, Canada.

CardioComm Solutions, Inc. trades as EKGGF on OTC. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in USD.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $271,935 of revenue and -$529,056 of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

CardioComm Solutions, Inc. can be compared against peers such as Cann American Corp., Certive Solutions Inc., DATATRAK International, Inc., InterCare DX, Inc., Medgroup Inc., Mitesco, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $908,878, beta of 1.00, and return on equity of +76.8%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

EKGGF currently shows total debt of $690,645 and beta of 1.00. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.cardiocommsolutions.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.